The Cancer Driver Genes IDH1 and IDH2 and CD204 in WHO-Grade 4 Astrocytoma: Crosstalk Between Cancer Metabolism and Tumour Associated Macrophage Recruitment in Tumour Microenvironment (original) (raw)

Association Between CD204-Expressed Tumor-Associated Macrophages and MGMT-Promoter Methylation in the Microenvironment of Grade 4 Astrocytomas

Shadi Alkhayyat

World Journal of Oncology

View PDFchevron_right

The prognostic impact of subclonal IDH1 mutation in grade 2–4 astrocytomas

Melissa Umphlett

Neuro-Oncology Advances

View PDFchevron_right

No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas

Andreas Unterberg

Journal of Neuro-Oncology, 2012

View PDFchevron_right

Vascular differences between glioblastoma IDH-wildtype and astrocytoma IDH-mutant grade 4 at imaging and transcriptomic level

Maria de la Iglesia Vayá

View PDFchevron_right

IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors

Paola Cassoni

Journal of Neuro-Oncology, 2011

View PDFchevron_right

Analysis of the prognosis of high-grade gliomas in the view of new immunohistochemistry markers and 2016 who classification

metehan ozturk

Turkish Neurosurgery, 2022

View PDFchevron_right

Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting

Arja Jukkola

Acta Neuropathologica Communications

View PDFchevron_right

Expression of CD44 and IDH1 R132H in Gliomas and their Prognostic Relevance

Arvids Jakovļevs

Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences., 2020

View PDFchevron_right

IDH1 Mutations in Diffusely Infiltrating Astrocytomas

K. Thennarasu

American Journal of Clinical Pathology, 2012

View PDFchevron_right

IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO

Yasin Mamatjan

Acta neuropathologica, 2015

View PDFchevron_right

Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas

Timothy Richardson

Acta Neuropathologica Communications

View PDFchevron_right

IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy

Koichi Ichimura

International journal of oncology, 2012

View PDFchevron_right

Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis

Michael Jansen

Acta Neuropathologica, 2010

View PDFchevron_right

Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis

Jonathan Serrano

Journal of neuro-oncology, 2017

View PDFchevron_right

Clinical, Morphological, and Molecular Study of Diffuse WHO Grade II and III Astrocytomas: A Retrospective Analysis from a Single Tertiary Care Institute

Rajesh Alugolu

Indian Journal of Medical and Paediatric Oncology, 2021

View PDFchevron_right

Immunohistochemical expression of IDH1 in gliomas: A tissue microarray-based approach

Ira Sharma

Journal of Cancer Research and Therapeutics, 2012

View PDFchevron_right

IDH1 and IDH2 mutations in gliomas

ROGER MCLENDON

New England Journal …, 2009

View PDFchevron_right

Systemic Immune Bias Delineates Malignant Astrocytoma Survival Cohorts

Michael Prosniak

The Journal of Immunology

View PDFchevron_right

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma

Olivia Sabunga

Asian Pacific Journal of Cancer Prevention

View PDFchevron_right

Metabolic alterations due to IDH1 mutation in glioma: opening for therapeutic opportunities?

Peter Van Der Spek

Acta neuropathologica communications, 2014

View PDFchevron_right

Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities

Andreas Unterberg

Acta neuropathologica, 2015

View PDFchevron_right

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas

Martin Van Den Bent

Acta neuropathologica, 2018

View PDFchevron_right

Prognosis in Idh-Mutant and Idh-Wild Type Glioblastoma

Reyhan Egilmez

Cumhuriyet Medical Journal, 2021

View PDFchevron_right

Subtyping of gliomas of various WHO grades by the application of immunohistochemistry

Anna Dimberg

Histopathology, 2014

View PDFchevron_right

Analysis of Isocitrate Dehydrogenase (IDH) expression in astrocytoma patients: cases of South Sulawesi, Indonesia

Olivia Sabunga

Bali Medical Journal, 2022

View PDFchevron_right